Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected
 impacts of policy alternatives: A mathematical modeling study

- 3
- 4 Yiran E Liu<sup>1,2</sup>, Yasmine Mabene<sup>2</sup>, Sergio Camelo<sup>3</sup>, Zulma Vanessa Rueda<sup>4,5</sup>, Daniele Maria
- 5 Pelissari<sup>6</sup>, Fernanda Dockhorn Costa Johansen<sup>6</sup>, Moises A Huaman<sup>7</sup>, Tatiana Avalos-Cruz<sup>8</sup>,
- 6 Valentina A Alarcón<sup>8</sup>, Lawrence M Ladutke<sup>9</sup>, Ted Cohen<sup>10</sup>, Jeremy D Goldhaber-Fiebert<sup>11,12</sup>,
- 7 Julio Croda<sup>10,13,14</sup>, Jason R Andrews<sup>2</sup>
- 8
- <sup>1</sup> Department of Epidemiology and Population Health, Stanford University, Stanford, California,
   USA.
- <sup>2</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford
- 12 University, Stanford, California, USA.
- <sup>13</sup> <sup>3</sup>Institute for Computational and Mathematical Engineering, Stanford University, Stanford,
- 14 California, USA.
- <sup>4</sup> Department of Medical Microbiology and Infectious Diseases, University of Manitoba,
- 16 Winnipeg, Canada.
- <sup>5</sup> School of Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia.
- <sup>6</sup>National Tuberculosis Program, Ministry of Health, Brasília, Brazil.
- <sup>7</sup> Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati
- 20 College of Medicine, Cincinnati, Ohio, USA.
- 21 <sup>8</sup> Dirección de Prevención y Control de la Tuberculosis, Ministerio de Salud, Lima, Perú.
- 22 <sup>9</sup>Amnesty International USA, New York, New York, USA.
- <sup>10</sup> Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University,
- 24 New Haven, Connecticut, USA.
- 25 <sup>11</sup> Department of Health Policy, Stanford University, Stanford, California, USA.
- <sup>12</sup> Center for Health Policy, Freeman Spogli Institute, Stanford University, Stanford, California,
- 27 USA.
- 28 <sup>13</sup> Departamento de Clínica Médica, Universidade Federal de Mato Grosso do Sul, Campo
- 29 Grande, Brazil.
- 30 <sup>14</sup> Fiocruz Mato Grosso do Sul, Campo Grande, Brazil.
- 31
- 32 Manuscript Word Count: 3750
- 33 Abstract Word Count: 250
- **Tables:** 2
- **Figures**: 4
- 36 **References:** 31
- 37
- 38 Correspondence:
- 39 Yiran E Liu
- 40 Stanford University School of Medicine
- 41 Department of Epidemiology and Population Health
- 42 300 Pasteur Drive
- 43 Stanford, California 94305
- 44 Email: <u>yiranliu@stanford.edu</u>
- 45

# 46 ABSTRACT (250 words)

47

# 48 Background

Tuberculosis incidence is increasing in Latin America, where the incarcerated population has nearly quadrupled since 1990. The full impact of incarceration on the tuberculosis epidemic,

- 51 accounting for effects beyond prisons, has never been quantified.
- 52

# 53 Methods

We calibrated dynamic compartmental transmission models to historical and contemporary data
 on incarceration and tuberculosis in Argentina, Brazil, Colombia, El Salvador, Mexico, and Peru.
 Together these countries comprise approximately 80% of the region's incarcerated population

57 and tuberculosis burden. Using historical counterfactual scenarios, we estimated the transmission

58 population attributable fraction (tPAF) for incarceration and the excess population-level burden

59 attributable to increasing incarceration prevalence since 1990. We additionally projected the

60 impact of various incarceration scenarios on future population tuberculosis incidence.

61

# 62 Findings

63 The rise in incarceration prevalence since 1990 has resulted in an estimated 30,241 (95% UI,

64 24,333 - 39,303) excess incident tuberculosis cases in 2019 across the six countries. The tPAF for

65 incarceration in 2019 was 23.5% (95% UI, 17.7-32.0), exceeding estimates for other key risk

66 factors like HIV, alcohol use disorders, and undernutrition. Compared to a base-case scenario 67 where current incarceration policies persist, decarceration interventions could reduce future

- 67 where current incarceration policies persist, decarceration interventions could reduce future 68 population tuberculosis incidence in all countries, notably by over 10% in Brazil, Colombia, El
- 69 Salvador, and Peru.
- 70

# 71 Interpretation

72 The historical rise in incarceration in Latin America has resulted in a large excess burden of

tuberculosis that has been under-recognized to-date. International health agencies, ministries of justice, and national tuberculosis programs should collaborate to address this health crisis with

- 75 comprehensive strategies, including decarceration.
- 76 77 **Funding**
- 78 National Institutes of Health
- 79

#### 80 Research in context

81

#### 82 Evidence before this study

83 We searched PubMed for studies on tuberculosis in prisons in Latin America, using the search 84 terms ("tuberculosis") AND ("prisons" OR "incarceration") AND ("Latin America" OR "Argentina" OR "Brazil" OR "Colombia" OR "El Salvador" OR "Mexico" OR "Peru"), 85 86 published in any language. Previous studies have identified a high risk of tuberculosis in prisons 87 in Latin America, finding that notifications in prisons are increasing and account for a growing 88 proportion of all cases in the region. Other national or sub-national studies have found elevated 89 tuberculosis risk among formerly incarcerated individuals and transmission chains spanning 90 prisons and communities. However, the full contribution of incarceration to the broader 91 tuberculosis epidemic in Latin America-accounting for historical incarceration trends, under-92 detection in prisons, and "spillover" effects into communities-has never been quantified. 93 Furthermore, previous studies have evaluated biomedical interventions in prisons; the regional 94 impact of alternative incarceration policies on future population tuberculosis incidence is 95 unknown.

96

# 97 Added value of this study

98 Here we quantify the full contribution of incarceration to the tuberculosis epidemic in Latin 99 America. Our model captures the dynamic nature of incarceration, incorporating historical and 100 contemporary data sources to account for varying prison turnover rates and mechanisms 101 underlying historical incarceration growth. By modeling the population with incarceration 102 history, we estimate the true size of the ever-exposed population, which across the six countries 103 is nearly 14 times the size of the population within prison at any one time. We identify the 104 settings where excess cases occur and compare our results to crude estimates based on 105 notifications in prisons. We show, across six countries with diverse carceral contexts and 106 tuberculosis epidemiology, that incarceration is a leading driver on par with other major 107 tuberculosis risk factors, a role that has been under-recognized to date. Finally, we demonstrate 108 the potential impact of alternative incarceration policies in reducing future tuberculosis burden in 109 carceral settings and the general population.

110

# 111 Implications of all the available evidence

112 To date the true impact of incarceration on the tuberculosis epidemic across the region has been

113 underestimated due to a narrow focus on disease occurring during incarceration. In light of the

substantial excess tuberculosis burden attributable to incarceration, interventions targeting

115 incarceration can have outsized effects on the broader tuberculosis epidemic in Latin America—

116 much greater than previously appreciated. These interventions should include not only strategies

117 to reduce tuberculosis risk among currently and formerly incarcerated individuals, but also

118 efforts to end mass incarceration.

# 119 **INTRODUCTION**

Globally, 10.6 million people developed tuberculosis in 2022<sup>1</sup>. While global tuberculosis incidence has decreased by 8.7% since 2015, in Latin America, tuberculosis incidence increased by 19% over the same period, highlighting the urgent need to address key tuberculosis drivers in the region.

124

In Latin America, the incarcerated population has nearly quadrupled over the last thirty years<sup>2</sup>. Persons deprived of liberty (PDL), who may already face elevated risk of tuberculosis prior to incarceration, are further exposed to prison conditions that foster transmission and disease progression, including overcrowding, poor ventilation, malnourishment, and limited access to health care<sup>3</sup>. Together these factors contribute to tuberculosis rates that, in South America, are 26 times higher among PDL than in the general population<sup>4</sup>.

131

132 Recognizing the crisis of tuberculosis in prisons, the Pan-American Health Organization (PAHO) 133 began requesting data from member states on case notifications occurring among PDL. Between 134 2014 and 2019, the percent of all notified tuberculosis cases in the region occurring among PDL increased from 6.6% to  $9.4\%^{3,5}$ . While alarmingly high, this figure underestimates the 135 136 tuberculosis burden attributable to incarceration, for several reasons. First, the case detection 137 ratio is lower in prisons than in the general population<sup>5</sup>. Second, individuals who acquire 138 infection in prison often do not progress to tuberculosis disease until after release. Indeed, 139 previous studies showed that formerly incarcerated individuals had elevated rates of tuberculosis for up to seven years following release from prison<sup>6,7</sup>. As notifications databases do not record 140 141 information on incarceration history, these cases are not currently attributed to incarceration<sup>8</sup>. 142 Finally, infections acquired in prisons, including among people who work in or visit prisons, can 143 spread in the community. Accordingly, genomic epidemiologic studies have identified tuberculosis transmission chains that span prisons and communities<sup>9-13</sup>. Therefore, existing 144 studies that focus on tuberculosis occurring in prisons overlook the role of incarceration as a 145 146 population-level tuberculosis driver.

147

148 Understanding the full contribution of incarceration to the worsening tuberculosis epidemic in 149 Latin America is critical to inform tuberculosis prevention strategies and resource allocation. 150 Furthermore, the impact of alternative incarceration policies on the tuberculosis epidemic 151 remains unknown, as previous studies have focused on biomedical interventions. In this study, 152 we use mathematical modeling to quantify the population-level burden of tuberculosis 153 attributable to incarceration in six countries: Argentina, Brazil, Colombia, El Salvador, Mexico, 154 and Peru. Specifically, we hypothesize that the rise in incarceration since 1990 has produced a 155 growing excess tuberculosis burden and hindered tuberculosis progress in the region. We 156 additionally simulate alternative incarceration policies and project their impact on future 157 population tuberculosis incidence.

158

# 159 METHODS

# 160 Setting

161 We selected countries in Latin America, defined as Mexico, Central America, and South America,

- 162 based on data availability and to represent regional heterogeneity in incarceration and 163 tuberculosis trends.
- 164

#### 165 *Data sources*

We collected data on incarceration prevalence, prison entries or releases, and recidivism from each country's penitentiary department or census agency via published reports and information requests (**Table S1, Appendix**). We also referenced reports and articles published by researchers, international agencies, and journalists. Population estimates and projections were obtained from the World Population Prospects. Population-wide tuberculosis notifications and incidence estimates were retrieved from the WHO Global Tuberculosis Report<sup>1</sup>. Notifications and incidence estimates for PDL were sourced from PAHO and a recent study<sup>5</sup> (**Table S2**).

- 173
- 174 Model development and calibration

175 We developed a deterministic, meta-population compartmental model to simulate incarceration 176 and tuberculosis transmission (Figure S1, Table S3, Appendix). The model includes a simple 177 representation of tuberculosis natural history across five compartments: susceptible, early latent, 178 late latent, infectious, and recovered. These compartments are replicated across four population 179 strata, which individuals traverse via incarceration and release: never incarcerated, currently 180 incarcerated, recent history of incarceration, and distant history of incarceration. We distinguish 181 between recent and distant incarceration history to account for the elevated risk of recidivism, tuberculosis, and mortality in the early period post-release<sup>6,7,14</sup>. The model does not include HIV, 182 183 drug resistance, or age structure and excludes children aged 14 years and under who are assumed 184 to not be at risk of incarceration. We include low levels of mixing between incarcerated and non-185 incarcerated individuals to represent interactions with prison staff and visitors.

186

187 We fit the model independently for each country to incarceration and tuberculosis data from 188 1990 to 2023. Yearly calibration targets included incarceration prevalence, prison entries 189 (admissions), and recidivism, as well as total and within-prison tuberculosis incidence and 190 notification rates (Tables S1-S2). We accounted for uncertainty by sampling from distributions 191 for calibration targets and for a subset of parameters that were fixed during calibration (Tables 192 S3-S4). For each sample of calibration targets and fixed parameters, we then ran optimization 193 algorithms to calibrate the remaining parameters, obtaining at least 1000 fitted parameter sets per 194 country.

195

For time-varying parameters, we let the model reach equilibrium with baseline values and then applied rates of change starting in the year 1990. Changes in incarceration prevalence over time were achieved through changes in prison entry and release rates; changes in tuberculosis incidence and notification rates were achieved through changes in effective contact rates, disease progression rates, and diagnosis rates (**Table S5**). We also accounted for COVID-19 pandemicrelated changes (**Table S6**).

- 202
- 203 Excess burden estimates

For each country, we quantified the excess population-level tuberculosis incidence attributable to the rise in incarceration prevalence since 1990 by simulating a counterfactual scenario where incarceration prevalence and dynamics remained constant at 1990 levels. To operationalize this, for each set of fitted parameters, we re-ran the model from 1990, with time-dependent changes in prison entry and release rates turned off. We also eliminated time-dependent changes in the effective contact rate within prison, which we assumed to be linked to growing prison populations. We then calculated the excess burden as the relative and absolute difference in population tuberculosis incidence between the observed and counterfactual scenarios. We report excess burden estimates in 2019 due to COVID-19-related uncertainty, but we include estimates for 2022 in the Appendix. We also analyze where excess incident cases arose—i.e., where individuals progressed or relapsed to infectious tuberculosis disease—and where cases were diagnosed and notified.

216

# 217 Sensitivity analyses and meta-modeling

218 We performed sensitivity analyses to test two assumptions. First, in the main analysis, we 219 assumed that the effective contact rate in prison could change over time due to observed 220 increases in prison tuberculosis notification rates that could not be solely explained by 221 improvements in case detection. We performed a sensitivity analysis holding the effective 222 contact rate in prison constant over time. Second, in the main analysis, we assumed proportionate 223 mixing among population strata outside of prison. In a sensitivity analysis, we implemented 224 assortative mixing in the community based on incarceration history. Holding total contact rates 225 constant, we increase the relative amount of intragroup mixing among formerly incarcerated 226 individuals to three times that in the main analysis.

227

We additionally conducted linear regression meta-modeling using a multi-level model to identify parameters associated with variation in excess burden estimates<sup>15</sup>. The Appendix includes methodological details for sensitivity analyses and meta-modeling, as well as meta-modeling results.

232

# 233 Transmission population attributable fraction (tPAF)

To estimate the tPAF for incarceration among individuals aged 15 and older, we simulated a scenario where incarceration prevalence was gradually reduced to zero by 2019 (**Appendix**). For

- each country, we calculated the tPAF for incident cases in 2019 as follows<sup>16</sup>:
- 237

$$tPAF = \frac{Pop.TB \ incidence_{observed} - Pop.TB \ incidence_{incarceration \ eliminated}}{Pop.TB \ incidence_{observed}}$$

238

We compared our estimates of the tPAF for incarceration with WHO's country-specific estimates of the fraction of all incident cases attributable to each of five major tuberculosis risk factors in 2019. We note that risk factors may be overlapping, and that WHO's estimates apply to varying age groups: undernutrition, all ages; HIV, all ages; alcohol use disorders, age  $\geq 15$ ; smoking, age  $\geq 15$ ; diabetes, age  $\geq 18$ . For diabetes, the PAF is reported as a fraction of all cases among individuals age  $\geq 15$ , rather than a true PAF, and therefore may be an overestimate.

- 245
- 246 *Future policy scenarios*

We simulated various incarceration scenarios over a ten-year period and estimated their impacts on future population tuberculosis incidence. Under the reference or "stable" scenario, prison entry and release rates remain constant for ten years. Under the "continue trends" scenario, entry and release rates undergo the same relative net change between 2024 and 2034 as they did over the prior ten years. The remaining decarceration scenarios involve pairwise combinations of 0-100% decreases in entry rates and increases in release rates, with the percent change target achieved linearly by the end of the ten-year period. We computed the percent difference in 254 projected population tuberculosis incidence in 2034 under each scenario compared to that 255 expected under the stable scenario.

256

257 For El Salvador, where the prison population has nearly tripled since March 2022 under a continued state of emergency<sup>17</sup>, we introduced additional parameters to model recent trends 258 (Table S7). We then simulated the following future scenarios: 1) continuation of current entry 259 260 and release rates under the state of emergency; 2) passive abatement through a gradual return to 261 pre-emergency entry and release rates; and 3-5) active cessation and reversion to pre-emergency 262 incarceration prevalence in ten, five, or two years, with continued decarceration thereafter. 263 Rather than comparing to a reference scenario, we computed the percent change in population 264 tuberculosis incidence in 2034 under each scenario compared to 2021. Methods for future 265 projections are detailed in the Appendix.

- 266
- 267 *Role of the funding source*

The funders had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the paper for publication.

# 270271 **RESULTS**

Argentina, Brazil, Colombia, El Salvador, Mexico, and Peru exhibited wide variability in the
population-wide and within-prison burden of tuberculosis between 1990 and 2019 (Figure 1).
Together, they represent 82.4% of the region's incarcerated population, 79.7% of total
tuberculosis notifications, and 80.1% of tuberculosis notifications in prisons in 2018.

276

277 Between 1990 and 2019, the prevalence of incarceration among the population aged 15 and older 278 more than doubled in all countries except Mexico, reaching 366 (range: 216 to 825) per 100,000 279 in 2019 across the six countries (Table 1). This historical rise was driven by an increase in prison 280 entry rates (Argentina and Brazil), an increase in average duration of incarceration (Peru), or 281 both (El Salvador, Colombia, Mexico) (Table S8). By 2019, the average duration of 282 incarceration ranged from 1.3 years (95% UI 0.9-2.1) in Brazil to 6.2 years (4.4-9.0) in El 283 Salvador (Table 1. Further, the percent of the prison population with prior incarceration history 284 ranged from 17% (95% UI 11-22) in El Salvador to 51% (39-59) in Brazil. Such differences in 285 incarceration dynamics contribute to the heterogeneity in community prevalence of incarceration 286 history among the population age 15 and older, which ranged from 1.6% (95% UI 1.0-2.3) in Argentina to 7.6% (4.9-10.7) in Mexico (Table 1). Across all six countries in 2019, while 1.3 287 288 million people were incarcerated at any given time, we estimate that an additional 16.7 million 289 (95% UI 12.9-21.0 million) people were living with incarceration history.

290

291 Compared to a counterfactual scenario where incarceration prevalence remained constant since 292 1990, the observed rise in incarceration prevalence since 1990 resulted in an estimated 30,241 293 (95% UI, 24,333-39,303) excess incident cases in 2019 across the six countries (Figure 2A-B, 294 Table 2). The excess population tuberculosis incidence in 2019 varied widely across countries, 295 ranging from 5% or 1.1 (95% UI 0.6-1.9) cases per 100,000 person-years in Mexico to 133% or 296 32.0 (25.6-40.7) cases per 100,000 person-years in El Salvador (Table 2). Estimates for the year 297 2022 were comparable (**Table S9**). Sensitivity analyses eliminating temporal changes in within-298 prison transmission rates, or assuming assortative mixing in the community by incarceration 299 history, did not substantively change our results (Table S10).

- 300
- The burden of excess incident cases that arose (i.e., progressed to disease or relapsed) in prisons
- in 2019 exceeded that of excess cases *diagnosed* within prisons by 37%, ranging from 11% in El Salvador to 104% in Colombia (**Figure 2C**). Furthermore, a considerable fraction of the excess
- 304 burden in 2019 was comprised of incident cases arising among formerly incarcerated individuals,
- 305 particularly in countries with shorter average duration of incarceration (**Figure 2C**). For instance,
- 306 the percent of excess cases arising in the community among formerly incarcerated individuals
- 307 was 39% (95% UI 26-57) in Argentina, 34% (21-47) in Brazil, and 34% (22-47) Mexico. In all
- 308 countries, estimated tuberculosis incidence rates among individuals with recent or incarceration 309 history were much higher than population-wide incidence rates (**Figure S2, Table S12**).
- 309 310
- 311 Collectively across countries, incarceration was the leading determinant compared to other key
- tuberculosis risk factors, accounting for an estimated 23.5% (95% UI, 17.7-32.0) of incident cases in 2019 among the population aged 15 and older. The country-specific tPAF of incarceration in 2019 reached 58.0% (95% UI, 51.6-63.5) in El Salvador, 31.8% (24.7-41.3) in
- Brazil, 19.5% (13.9-20.0) in Peru, 18.9% (12.2-28.8) in Colombia, 7.7% (5.2-16.3) in Argentina, and 6.4% (4.0-9.8) in Mexico (**Table 2**). Despite this variability, the country-specific tPAF for incarceration was consistently greater than or commensurate with PAFs for other major risk factors (**Figure 3**). Moreover, our median tPAF estimate was 1.3 to 5.3 times the percent of all
- tuberculosis notifications occurring in prisons in 2019 (Figure 3).
- 320

321 We projected the impact of future incarceration policies, implemented from 2024 to 2034, on 322 population tuberculosis incidence in 2034. Future projections for El Salvador are described 323 further below. For all other countries, projected incarceration prevalence in 2034 under each 324 scenario is shown in **Figure 4A** and **Table S13.** If recent incarceration trends continue, projected 325 population tuberculosis incidence in 2034 would be slightly (<3%) higher in Peru, Argentina, 326 and Mexico, and slightly lower in Colombia and Brazil (Figure 4B). More active decarceration 327 interventions-for instance, a simultaneous 50% decrease in entry rates and 50% increase in 328 release rates—could reduce population tuberculosis incidence in 2034 by an estimated 21.0% (95% 329 UI 13.8-29.1) in Brazil, 10.8% (7.5-15.6) in Peru, 10.0% (5.8-15.8) in Colombia, 7.5% (4.6-12.8) 330 in Argentina, and 1.0% (0.3-3.0) in Mexico. Results for additional interventions are shown in 331 Figure S3.

332

333 In El Salvador, maintaining the current state of emergency is projected to increase population 334 tuberculosis incidence in 2034 by 126% (95% UI 71-193) compared to pre-emergency in 2021 (Figure 4C). A gradual, passive abatement of the state of emergency would still increase 335 336 population tuberculosis incidence in 2034 by a projected 43% (95% UI 18-74). In contrast, 337 prompt and active cessation of the state of emergency and reversion of incarceration prevalence 338 to approximate pre-emergency levels by 2034 could restore population tuberculosis incidence in 339 2034 to its approximate rate in 2021. More decisive actions to revert pre-emergency 340 incarceration prevalence in two or five years and continue further decarceration thereafter could 341 reduce population tuberculosis incidence in 2034 by as much as 29% (95% UI 21-37) compared 342 to 2021.

- 343
- 344 **DISCUSSION**

345 Across six Latin American countries, more than 30,000 incident cases in 2019 can be attributed 346 to the rise in incarceration since 1990. Collectively in these countries, incarceration accounts for 347 an estimated 23.5% (17.7-32.0) of incident cases in 2019 among individuals aged 15 and older, a 348 greater fraction than any other determinant. Against the backdrop of the region's alarming increase in tuberculosis incidence over the last decade, we project that policies to reduce 349 350 incarceration prevalence may considerably reduce future population tuberculosis incidence. 351 Together, our results implicate incarceration as a leading population-level driver of the 352 tuberculosis epidemic in Latin America. In addition to improving prison conditions and 353 implementing biomedical interventions in prisons, criminal legal reforms and development of 354 non-carceral alternatives will be critical to re-ignite progress towards tuberculosis elimination.

355

356 Our findings reveal how the population-level impact of incarceration on tuberculosis has been 357 previously under-recognized by conventional approaches that rely on case notifications within prisons<sup>3,18-21</sup>. Such approaches overlook not only under-detection in prisons but also the highly 358 dynamic nature of incarceration. The constant flow of people who are newly incarcerated and 359 360 released yields a much larger population ever exposed to the high-risk carceral environment, 361 which we estimate across the six countries is nearly 14 times the size of the population in prison 362 at any given time. By using a dynamic model, we were able to account for this phenomenon and 363 its interplay with the variable latent period of tuberculosis, under-detection in prisons, and 364 onward transmission in the community. As a result, we obtained tPAF estimates that far exceeded 365 the percent of notified tuberculosis cases occurring in prisons, and that increased the rank of 366 incarceration relative to other major TB determinants. Policy guidance and future research should recognize incarceration as a dynamic state whose role as a tuberculosis driver and social 367 368 determinant transcends effects observable within prisons.

369

370 We also demonstrate the potential impact of alternative incarceration policies on the tuberculosis 371 epidemic in the region. For instance, policies that restore incarceration prevalence to levels 372 previously observed since 1990 could reduce future population tuberculosis incidence by more 373 than 10% in Brazil, Peru, and Colombia, countries which encompass the vast majority of the 374 region's tuberculosis burden. In Brazil, an intervention that reverts incarceration prevalence to its 375 2000 level would reduce population TB incidence by a projected 21.0%-greater than the country's net 15.7% reduction achieved between 2000 and 2015<sup>18</sup>. In El Salvador, which already 376 377 had an exorbitant tPAF for incarceration prior to 2022, the state of emergency is projected to 378 have catastrophic consequences for tuberculosis. We predict that swift, resolute termination of 379 the state of emergency could enable a return to pre-emergency incidence by 2034, and that 380 further decarceration can recover, at least in part, a decade of lost opportunity for tuberculosis 381 progress. Such measures have precedent in Kazakhstan, where KNCV and Penal Reform 382 International co-led comprehensive efforts to address tuberculosis in prisons, integrating 383 biomedical interventions with decriminalization reforms, implementation of alternatives to incarceration, and improvements in prison conditions<sup>22</sup>. Following expansion of the program in 384 385 2000, incarceration prevalence decreased by 70% and with it, the rate of tuberculosis in prisons by 90%<sup>23</sup>. Therefore, decarceration interventions, especially if coupled with biomedical 386 387 interventions and efforts to improve prison conditions, have substantial potential to accelerate 388 progress towards 2035 End TB strategy targets.

390 Our estimates of the tuberculosis burden attributable to incarceration vary greatly across the six 391 countries included, correlating strongly with country-specific disparities in tuberculosis risk 392 between prisons and the general population. Between-country variation in where excess cases 393 occur can also be attributed to distinct carceral dynamics across countries. For instance, in 394 countries with a longer average duration of incarceration, like El Salvador and Peru, our model 395 predicts that the vast majority of excess incident cases occur within prisons<sup>5</sup>. Conversely, in 396 countries with a shorter average duration of incarceration, i.e., Brazil and Mexico, a greater 397 proportion of excess incident cases occur in the community after prison release. Therefore, it is 398 crucial to consider incarceration dynamics and changing carceral policies in identifying optimal 399 intervention strategies.

400

401 In response to this public health crisis, bold and decisive investments and actions are needed. 402 First, international health agencies and national tuberculosis programs must improve reporting of 403 incarceration as a structural determinant of tuberculosis. This includes collecting information on 404 incarceration history in case notifications databases and including current and past incarceration 405 as a key risk factor in WHO's Global Tuberculosis Report<sup>8</sup>. Given the stigma and discrimination 406 faced by individuals with incarceration history, guidance should be developed with stakeholders to collect this information in a sensitive manner<sup>24</sup>. Second, effective strategies to prevent, detect, 407 408 and treat tuberculosis in incarcerated and formerly incarcerated individuals must be identified, incorporated in national guidelines, and implemented at scale<sup>25,26</sup>. While existing research has 409 focused on prison-based interventions, future work should expand to include formerly 410 411 incarcerated individuals and their community contacts.

412

413 Lastly, and equally as important, governments must implement structural reforms to reduce the 414 prison population. Rising incarceration in the region has contributed to severe prison 415 overcrowding, which is correlated with tuberculosis incidence in prisons<sup>2,5</sup>. While our study focused on tuberculosis, incarceration exposure has been linked to other adverse health 416 outcomes<sup>14,27,28</sup>. Therefore, decarceration strategies, especially in conjunction with efforts to 417 418 transform conditions of imprisonment, have the potential to both accelerate tuberculosis progress 419 and improve population health at large. Such strategies should be formulated with key 420 stakeholders but may include reforms to reduce pre-trial detention, decriminalize drug use and 421 mental illness, develop and scale restorative justice-based alternatives to imprisonment, and invest in preventative social, health, and welfare services<sup>29,30</sup>. 422

423

424 Our study has several limitations. First, deterministic compartmental models are unable to 425 capture the full range of complexity in real-world phenomena. The extent to which we were able 426 to incorporate complexity in our model was constrained by inadequate data to inform model 427 parameters and assumptions. For instance, our model did not account for age, gender, 428 socioeconomic status, HIV, heterogeneity in duration of incarceration, nor heterogeneity in infectiousness. We also did not model MDR-TB, which is less common in prisons in the 429 Americas than in other regions<sup>31</sup>. Moreover, we had little to no data to inform mixing 430 431 assumptions or stratum-specific parameters for formerly incarcerated individuals. In these cases 432 of insufficient data, we used wide parameter uncertainty distributions and varied our assumptions 433 in sensitivity analyses, with our findings generally remaining robust. However, the dearth of 434 reliable, publicly accessible data on incarceration and tuberculosis must be urgently addressed.

436 Next, our future projections are subject to great uncertainty, including uncertainty around how 437 the COVID-19 pandemic has affected and will continue to affect tuberculosis and incarceration. We were unable to model specific policies or reforms (i.e., decriminalization of drug use) due to 438 439 insufficient data. Our future simulations also do not include changes in any other dimension 440 aside from prison entry and release rates, such as improvements in prison conditions or scale-up of biomedical interventions. Generally, our historical counterfactual and future policy 441 442 simulations are simplistic, modifying incarceration in isolation from what is inevitably an 443 intricate web of upstream and downstream social, economic, political, and institutional forces 444 that themselves also affect population health and tuberculosis. Nonetheless, our findings underscore the substantial potential for criminal legal reforms to reduce tuberculosis burden in 445 Latin America, impacts which could be enhanced by additional prison- and community-based 446 447 interventions.

448

449 To date we have failed to appreciate the full extent to which rising incarceration has undermined 450 tuberculosis control in Latin America. Our estimates of the outsized tuberculosis burden 451 attributable to incarceration eclipse those of other determinants that currently receive far greater 452 attention. However, this exceptional excess burden must not be regarded as inevitable. Health 453 agencies, national tuberculosis programs, ministries of justice, and other key stakeholders should 454 undertake bold commitments and actions to elevate the prominence of incarceration in national 455 and international strategies for tuberculosis control and elimination, accounting for impacts 456 beyond prison walls. These strategies should take an integrated health and human rights 457 approach, combining biomedical interventions and improvements in prison conditions with 458 actions to enable decarceration. Such measures will be critical to advancing towards regional and 459 global tuberculosis elimination targets.

#### 460 Table 1. Incarceration- and tuberculosis-related characteristics by country. All population-

461 wide prevalence estimates are for the population aged 15 and older.

	Argentina	Brazil	Colombia	El Salvador	Mexico	Peru
Incarcerated population in 1990*	21,016	90,000	32,387	5,982	93,119	17,859
Incarcerated population in 2019	109,405	755,274	123,078	38,114	200,936	95,548
Prison occupancy (%)^	112	165	146	333	97	219
Prevalence of incarceration per 100,000 in 2019	321	452	316	825	216	399
Percent increase in prevalence of incarceration since 1990**	250 (242, 255)	401 (398, 404)	133 (124, 142)	372 (335, 405)	39 (37, 41)	198 (179, 208)
Incarceration growth driven by increasing entry rates and/or duration?	Entry rates	Entry rates	Both	Both	Both	Duration
Average duration of incarceration (years) <sup>#</sup>	2.6 (1.8, 3.7)	1.3 (0.9, 2.1)	3.1 (2.3, 4.9)	6.2 (4.4, 9.0)	2.0 (1.4, 3.1)	5.7 (4.2, 8.3)
Within-prison prevalence of incarceration history (%) <sup>#</sup>	29 (20, 36)	51 (39, 59)	20 (14, 26)	17 (11, 22)	23 (16, 29)	26 (18, 32)
Community prevalence of incarceration history (%) <sup>#</sup>	1.6 (1.0, 2.3)	3.4 (1.9, 5.4)	5.7 (3.3, 7.9)	3.4 (2.4, 4.6)	7.6 (4.9, 10.7)	4.4 (3.1, 5.5)
Population-level tuberculosis notifications in 2019	11,446	85,523	14,292	3,009	23,702	31,764
Population tuberculosis notification rate per 100,000 in 2019	25.7	40.5	28.7	47.9	19.0	97.6
Prison tuberculosis notification rate per 100,000 in 2019	214	1303	784	3484	144	2945
Percent of all tuberculosis notifications occurring in prisons in 2019	2.0	11.5	6.8	44.1	1.2	8.9

\*Data are from 1992 for Argentina. ^Estimates from World Prison Brief in 2018. <sup>#</sup>Median and 95% 462 uncertainty intervals from at least 1000 model fits per country.

463

**Table 2. Estimates of population tuberculosis incidence attributable to incarceration in 2019.** All estimates are at the population-level among individuals aged 15 and older. Incidence rate ratios and excess burden estimates were obtained from comparing incident tuberculosis cases between the observed scenario of the historical rise in incarceration and the counterfactual scenario of no change in incarceration prevalence since 1990. The population attributable fraction was estimated using a scenario where incarceration prevalence was reduced to zero by 2019. 95% uncertainty intervals are shown in parentheses.

472

	Incidence rate ratio for observed vs. counterfactual	Excess cases per 100,000 person- years relative to counterfactual	Absolute excess cases relative to counterfactual	Population attributable fraction (%)
Argentina	1.05 (1.04, 1.13)	1.4 (0.9, 3.5)	469 (321, 1189)	7.7 (5.2, 16.3)
Brazil	1.36 (1.26, 1.51)	12.0 (9.0, 16.9)	20067 (15001, 28172)	31.8 (24.7, 41.3)
Colombia	1.22 (1.13, 1.39)	5.9 (3.5, 10.5)	2296 (1381, 4093)	18.9 (12.2, 28.8)
El Salvador	2.33 (2.04, 2.66)	32.5 (26.2, 41.6)	1502 (1211, 1921)	58.0 (51.6, 63.5)
Mexico	1.05 (1.03, 1.08)	1.1 (0.6, 1.9)	1015 (577, 1739)	6.4 (4.0, 9.8)
Peru	1.18 (1.11, 1.29)	18.6 (11.0, 31.4)	4451 (2623, 7515)	19.5 (13.9, 29)

# 474 **FIGURE LEGENDS**

475

Figure 1. Geographic, demographic, and epidemiologic heterogeneity among included
countries. Countries included in the analysis are highlighted in color; remaining countries in
Latin America are depicted in grey. Incarceration prevalence refers to the number of people per
100,000 population who are incarcerated at a given point in time. Tuberculosis (TB) notification
rates are per 100,000 person-years. Data on prison tuberculosis notifications are only available
starting in 2000. Latin America includes Mexico, Central America, and South America.

482

483 Figure 2. Excess population tuberculosis incidence attributable to the rise in incarceration 484 prevalence since 1990. A) Population tuberculosis incidence per 100,000 person-years under the 485 observed and counterfactual (no rise in incarceration since 1990) scenarios. Black points 486 represent population tuberculosis (TB) incidence estimates from the World Health Organization, 487 which are available beginning in 2000. Solid lines and shaded bands represent the median and 95% 488 UI respectively. B) Excess population-wide incident tuberculosis cases per 100,000 person-years. 489 C) Median estimates of excess cases, stratified by population subgroup in which they occurred, 490 and for incident cases occurring in prison, additionally stratified by whether the disease was 491 notified or undetected during incarceration. All model results are for the population age 15 and older.

492 493

494 Figure 3. Population attributable fraction for incarceration and other tuberculosis risk 495 factors. Median estimates and uncertainty intervals for the percent of population-level incident 496 tuberculosis cases in 2019 that can be attributed to each risk factor. The "crude" population 497 attributable fraction for incarceration, representing the percent of all notified tuberculosis cases 498 occurring in prisons, is shaded in dark red. Risk factors are listed in descending order by PAF for 499 each country. Estimates correspond to different age groups: incarceration, age  $\geq 15$ ; 500 undernutrition, all ages; HIV, all ages; alcohol, age  $\geq 15$ ; smoking, age  $\geq 15$ ; diabetes, age  $\geq 18$ 501 (see Methods).

502

503 Figure 4. Projected impacts of incarceration-related interventions on future population 504 tuberculosis incidence. A) Median incarceration prevalence per 100,000 population aged 15 and 505 older under incarceration scenarios implemented between 2024 and 2034: stable entry and 506 release rates (reference scenario), continuation of trends from prior ten years, 25% or 50% 507 reduction in prison entry rates by 2034, 25% or 50% increase in release rates by 2034, or 25% or 508 50% change in both entry and release rates by 2034. The dashed horizontal line represents 509 incarceration prevalence in 1990. B) Percent difference in population tuberculosis incidence in 510 2034 under each incarceration scenario, relative to the reference scenario of stable entry and 511 release rates. Outliers are not shown. C) Left: Median incarceration prevalence under each 512 incarceration scenario in El Salvador: continuation of entry and release rates under the state of 513 emergency, passive abatement through gradual reversion of entry and release rates to pre-514 emergency levels by 2034, active cessation and approximate restoration of pre-emergency 515 incarceration prevalence in ten years, or restoration of pre-emergency prevalence in five years or 516 two years with continued decarceration thereafter. The dashed horizontal line represents 517 incarceration prevalence in 1990. Right: Percent change in population TB incidence since 2021 518 under each scenario.

#### 521 **REFERENCES**

- 522 1. Global Tuberculosis Report 2023: World Health Organization, 2023.
- 523 2. (ICPR); IfCJPR. World Prison Brief.
- 524 3. Walter KS, Martinez L, Arakaki-Sanchez D, et al. The escalating tuberculosis crisis in 525 central and South American prisons. *The Lancet* 2021; **397**(10284): 1591-6.

526 4. Cords O, Martinez L, Warren JL, et al. Incidence and prevalence of tuberculosis in 527 incarcerated populations: a systematic review and meta-analysis. *The Lancet Public Health* 2021.

- 528 5. Martinez L, Warren JL, Harries AD, et al. Global, regional, and national estimates of 529 tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a 530 systematic analysis. *The Lancet Public Health* 2023; **8**(7): e511-e9.
- 531 6. Mabud TS, de Lourdes Delgado Alves M, Ko AI, et al. Evaluating strategies for control 532 of tuberculosis in prisons and prevention of spillover into communities: An observational and 533 modeling study from Brazil. *PLOS Medicine* 2019; **16**(1): e1002737.
- 534 7. Sequera G, Estigarribia-Sanabria G, Aguirre S, et al. Excess tuberculosis risk during and
   535 following incarceration in Paraguay: a retrospective cohort study. *The Lancet Regional Health –* 536 *Americas*.
- 537 8. Guillermo S, Sarita A, Gladys E, et al. Incarceration and TB: the epidemic beyond prison
  538 walls. *BMJ Global Health* 2024; 9(2): e014722.
- 539 9. Walter KS, Pereira dos Santos PC, Gonçalves TO, et al. The role of prisons in
  540 disseminating tuberculosis in Brazil: A genomic epidemiology study. *The Lancet Regional*541 *Health Americas* 2022; 9.
- 542 10. Warren JL, Grandjean L, Moore DAJ, et al. Investigating spillover of multidrug-resistant
  543 tuberculosis from a prison: a spatial and molecular epidemiological analysis. *BMC Medicine*544 2018; 16(1): 122.
- 545 11. Sanabria GE, Sequera G, Aguirre S, et al. Phylogeography and transmission of
  546 Mycobacterium tuberculosis spanning prisons and surrounding communities in Paraguay. *Nature*547 *Communications* 2023; 14(1): 303.
- 548 12. Utpatel C, Zavaleta M, Rojas-Bolivar D, et al. Prison as a driver of recent transmissions
  549 of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study. *The Lancet Regional*550 *Health Americas*.
- 551 13. Trevisi L, Brooks MB, Becerra MC, et al. Who Transmits Tuberculosis to Whom: A
- 552 Cross-Sectional Analysis of a Cohort Study in Lima, Peru. American Journal of Respiratory and
   553 Critical Care Medicine 2024.
- Liu YE, Lemos EF, Gonçalves CCM, et al. All-cause and cause-specific mortality during
  and following incarceration in Brazil: A retrospective cohort study. *PLOS Medicine* 2021; **18**(9):
  e1003789.
- 557 15. Jalal H, Dowd B, Sainfort F, Kuntz KM. Linear regression metamodeling as a tool to 558 summarize and present simulation model results. *Med Decis Making* 2013; **33**(7): 880-90.
- 559 16. Mishra S, Baral SD. Rethinking the population attributable fraction for infectious 560 diseases. *The Lancet Infectious Diseases* 2020; **20**(2): 155-7.
- 561 17. Régimen de excepción. <u>https://www.asamblea.gob.sv/taxonomy/term/1922</u> (accessed 562 Feburary 12 2024).
- 563 18. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 2:
- 564 Screening Systematic Screening for Tuberculosis Disease, 2021.

565 19. World Health Organization. Tuberculosis in prisons. 2023.
 566 <u>https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-</u>
 567 <u>2023/featured-topics/tb-in-prisons</u>.

- 568 20. Pelissari DM, Diaz-Quijano FA. Impact of incarceration on tuberculosis incidence and its 569 interaction with income distribution inequality in Brazil. *Transactions of The Royal Society of* 570 *Tropical Medicine and Hygiene* 2020; **114**(1): 23-30.
- 571 21. Li Y, de Macedo Couto R, Pelissari DM, et al. Excess tuberculosis cases and deaths 572 following an economic recession in Brazil: an analysis of nationally representative disease 573 registry data. *The Lancet Global Health* 2022; **10**(10): e1463-e72.
- 574 22. Atabay T, Laticevschi V, Vasil'eva TF. Human Rights and Health in Prisons: a review of
  575 strategy and practice: Penal Reform International and Royal Netherlands Tuberculosis
  576 Foundation (KNCV), 2006.
- 577 23. Pak S. Reforming the prison system: focusing on pre-trial detainees. Prison TB Alliance
  578 Meeting. Asuncion, Paraguay; 2024.
- 579 24. Sue K. How to Talk with Patients about Incarceration and Health. *AMA J Ethics* 2017; 580 **19**(9): 885-93.
- 581 25. Charalambous S, Velen K, Rueda Z, et al. Scaling up evidence-based approaches to tuberculosis screening in prisons. *The Lancet Public Health* 2023; **8**(4): e305-e10.
- 583 26. Narayan A, Salindri AD, Keshavjee S, et al. Prioritizing persons deprived of liberty in 584 global guidelines for tuberculosis preventive treatment. *PLOS Medicine* 2023; **20**(10): e1004288.
- 585 27. Silverman-Retana O, Servan-Mori E, Bertozzi SM, Orozco-Nuñez E, Bautista-Arredondo
- 586 S, Lopez-Ridaura R. Prison environment and non-communicable chronic disease modifiable risk 587 factors: length of incarceration trend analysis in Mexico City. *Journal of Epidemiology and* 588 *Community Health* 2018; **72**(4): 342-8.
- 589 28. Marmolejo L, Barberi D, Bergman M, Espinoza O, Fondevila G. Responding to COVID-
- 590 19 in Latin American Prisons: The Cases of Argentina, Chile, Colombia, and Mexico. *Victims & Offenders* 2020; **15**(7-8): 1062-85.
- 592 29. United Nations. United Nations System Common Position on Incarceration. 2021.
- 30. Broach S, Petrone M, Ryan J, Sivaram A. Reservoirs of Injustice: How incarceration for
  drug-related offenses fuels the spread of tuberculosis in Brazil: Yale Law School; Yale School of
  Public Health;, 2019.
- 596 31. Gygli SM, Loiseau C, Jugheli L, et al. Prisons as ecological drivers of fitness-
- 597 compensated multidrug-resistant Mycobacterium tuberculosis. *Nat Med* 2021; **27**(7): 1171-7.
- 598



Incarceration Scenario — Observed — No Change Since 1990

![](_page_18_Figure_1.jpeg)

![](_page_19_Figure_0.jpeg)

Α

![](_page_20_Figure_1.jpeg)